Plug-shaped implant for the replacement and regeneration of biological tissue and method for preparing said implant - Patents.com

A non-biodegradable plug-shaped implant with thermoplastic elastomer materials addresses the inadequacies of current osteochondral defect treatments by regenerating cartilage tissue, reducing the need for invasive joint replacement.

JP7596318B2Active Publication Date: 2024-12-09JOINTSPHERE BV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021576652
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-06-27
Filing Date
2020-06-23
Publication Date
2024-12-09
Estimated Expiration
2040-06-23

AI Technical Summary

Technical Problem

Current treatments for osteochondral defects, such as osteoarthritis, are inadequate in providing long-term regeneration of articular cartilage and often lead to joint replacement, which is invasive and costly.

Method used

A non-biodegradable plug-shaped implant with a base section for bone anchoring and upper/middle sections for cartilage regeneration, made of thermoplastic elastomer materials, including urethane and urea groups, that promotes cartilage tissue growth and repair.

Benefits of technology

The implant effectively regenerates cartilage tissue, potentially postponing or preventing the need for joint replacement by distributing load and promoting durable cartilage repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596318000003
    Figure 0007596318000003
  • Figure 0007596318000004
    Figure 0007596318000004
  • Figure 0007596318000005
    Figure 0007596318000005
Patent Text Reader

Abstract

1. A non-biodegradable implant for the replacement and regeneration of biological tissue in the form of a plug, comprising: a base section (2) configured to be fixed to bone tissue; a middle section (3) configured to replace cartilage tissue in the middle and deep zones of the cartilage layer and having a thickness of at least 0.2 mm; and an upper section (4) configured to allow cartilage tissue to grow on and into it, thus regenerating the superficial zone of the cartilage layer, wherein the middle and upper sections comprise the same thermoplastic elastomer material, which is porous in the upper section and non-porous in the middle section, the thermoplastic elastomer material comprising a linear block copolymer comprising urethane and urea groups, and is substantially free of additional peptide compounds having cartilage regeneration properties; and the base section material comprises one of a biocompatible metal, such as titanium or a titanium alloy, a ceramic, such as sintered crystalline hydroxyapatite, a mineral, such as a phosphate mineral, and a polymer, optionally a hydrogel polymer, and combinations thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an implant for the replacement and regeneration of living tissue in the form of a plug.The present invention particularly relates to an implant for the replacement and regeneration of osteochondral structures in the form of a plug.The present invention further relates to a method for the preparation of the implant and to an osteochondral structure comprising the implant. [Background technology]

[0002] Osteochondral structures refer to structures that include cartilage and bone. Typical osteochondral structures can be found in the thighbone (femur), shinbone (tibia), and kneecap (patella). Such structures fit together and move smoothly because the bone surfaces are covered with a relatively thick layer of articular (hyaline) cartilage. An (osteochondral) defect is any type of damage to the articular cartilage and optionally the underlying (subchondral) bone. Usually, (osteochondral) defects appear in certain weight-bearing spots, for example, at the ends of the femur and tibia, and behind the kneecap. These can range from rough cartilage, small bone and cartilage fragments that impede movement, to complete cartilage loss.

[0003] Trauma to the articular surface is common in young active people performing sports or following accidents. The lesion may involve only the cartilage layer, but often also the underlying subchondral bone. Articular cartilage has a very low tendency to heal, and the repair tissue is qualitatively inferior to the original tissue. This invariably leads over the years to the formation of osteoarthritis (OA), which is the main cause of disability and reduced quality of life in the elderly. The standard treatment for this condition is eventually joint replacement with an artificial joint. Although clinically effective, non-biological implants do not last longer than 10-20 years, and revision surgeries are much less effective and very costly. For this reason, much research has been dedicated to the development of biological regenerative treatments that last a lifetime. However, despite promising in vitro results, so far no single solution has proven to be more effective than the current standard treatment over the long term in real life conditions.

[0004] Because the cartilage layer lacks nerve fibers, patients are often unaware of the severity of the damage. During the final stage, the affected joint consists of rubbing with the bone, resulting in severe pain and limited mobility. By the time the patient seeks medical attention, surgical intervention may be required to relieve the pain and repair the cartilage damage. To avoid or postpone such surgical intervention, implants for joints have been developed. These can be embedded into the bone structure at an early stage of cartilage damage and thus offered for preventive treatment to avoid unnoticed degeneration of the joint.

[0005] Many treatment methods are available to treat articular cartilage damage in joints such as the knee, starting with the most conservative and non-invasive options and ending with total joint replacement if the damage has spread throughout the joint. Currently available treatments include anti-inflammatory drugs in the early stages. These can relieve pain, but have limited impact on arthritic symptoms and do not further repair the articular tissue. Cartilage repair methods such as arthroscopic debridement attempt to at least slow the degeneration of the tissue. However, these methods are only partially effective in repairing the soft tissue and do not restore the joint spacing or improve joint stability. Joint replacement surgery (arthroplasty) is considered the final solution when all other options to relieve pain and restore mobility have failed or are no longer effective. Although arthroplasty can be effective, the procedure is extremely invasive, technically challenging, and may compromise future treatment options. Cartilage regeneration has also been attempted, more specifically by tissue engineering techniques. The use of cells, genes and growth factors in combination with scaffolds plays a fundamental role in the regeneration of functional and viable articular cartilage. All these approaches are based on stimulating the body's normal healing or repair processes at the cellular level. Many of these compounds are delivered on a variety of carriers or matrices, including woven polylactic acid-based polymers or collagen fibers. Despite various attempts to regenerate cartilage, there is currently no reliable and proven treatment for repairing articular cartilage defects.

[0006] Another standard treatment is for smaller lesions (≤2cm 2 The current treatments consist of microfractures (MFx) for small lesions (>2 cm2) and autologous chondrocyte implantation (ACI) for larger lesions (>2 cm2). However, the cartilage tissue regenerated with these techniques cannot withstand the biomechanical challenges of the joint and starts to degenerate already within 18 months. Therefore, a significant delay in joint replacement with artificial joints is not possible, let alone preventing it. Summary of the Invention

[0007] The object of the present invention is to provide an implant for the replacement and regeneration of biological tissue in the form of a plug with improved load distribution and cartilage regeneration properties. Another object is to provide such an implant in the form of a plug for the replacement and regeneration of osteochondral structures. Yet another object is to provide a method for the preparation of the implant. The present invention further aims to provide an implant that can repair articular cartilage lesions in a durable manner, at least postponing and preferably preventing joint replacement with an artificial joint.

[0008] These and other objects are provided by a plug-shaped implant according to claim 1. In particular, the plug-shaped non-biodegradable implant comprises a base section adapted for fixing to bone tissue, a middle section adapted for replacing the cartilage tissue of the middle and deep zones of the cartilage layer and having a thickness of at least 0.2 mm, and a top section adapted for growing the cartilage tissue on and into it, thus regenerating the superficial zone of the cartilage layer, the middle and top sections comprising the same thermoplastic elastomer material, which is porous in the top section and non-porous in the middle section, the thermoplastic elastomer material comprising a linear block copolymer comprising urethane and urea groups, and substantially free of additional peptide compounds having cartilage regeneration properties, the base section material comprising one of biocompatible metals, ceramics, minerals such as phosphate minerals, and polymers, optionally hydrogel polymers, and combinations thereof. Preferably, the thermoplastic elastomer material is substantially free of any additional compounds having cartilage regeneration properties.

[0009] In cartilage, a relatively thin superficial (tangential) zone protects the deeper layers from shear stresses and accounts for approximately 10%–20% of the thickness of articular cartilage. The collagen fibers (mainly type II and IX collagen) in this zone are tightly packed and aligned parallel to the articular surface (Figure 2). The superficial zone contains a relatively large number of flattened chondrocytes, and the integrity of this layer is essential for the protection and maintenance of the deeper layers. This zone is in contact with the synovial fluid and is responsible for most of the tensile properties of cartilage, which allows it to resist the shear, tensile, and compressive forces exerted by the joint.

[0010] Just below the superficial zone, in the deep or inferior part, is the intermediate (intercalated or transitional) zone, which provides an anatomical and functional bridge between the superficial and deep zones. The intermediate zone comprises 40%-60% of the total cartilage volume and contains proteoglycans and thicker collagen fibrils. In this layer, the collagen is organized obliquely and the chondrocytes are globular and sparsely packed. Functionally, the intermediate zone is the first line of resistance to compressive forces.

[0011] Given that the collagen fibrils are oriented perpendicular to the articular surface, the deep zone of cartilage is responsible for providing the greatest resistance to compressive forces. The deep zone contains the largest diameter radially arranged collagen fibrils, the greatest proteoglycan content, and the lowest water concentration. Chondrocytes are typically arranged columnarly, parallel to the collagen fibers and perpendicular to the joint line. The deep zone represents approximately 30% of the volume of articular cartilage.

[0012] The base section material can be made of any suitable material that provides an adequate level of mechanical support to the surrounding bone and preferably allows bone formation. The suitable materials, including the thermoplastic elastomer materials of the middle and upper sections of the implant, are biocompatible, meaning that these materials are capable of coexisting with living tissues or organisms without harming them. Furthermore, the implant according to the present invention is substantially non-biodegradable and combines cartilage replacement and cartilage regeneration. Non-biodegradable materials in the context of the present invention mean materials that are not degraded by the environment of the implanted implant into less complex compounds or compounds with fewer carbon atoms. The weight average molecular weight of the substantially non-biodegradable material decreases by at most 20%, more preferably at most 10%, even more preferably at most 5%, and even more preferably still at most 1% compared to the original weight average molecular weight after one year of implantation.

[0013] Suitable metals for the base section material include, but are not limited to, titanium, zirconium, chromium, aluminum, stainless steel, hafnium, tantalum or molybdenum, and alloys thereof, or any combination thereof. Optionally, a surface layer of the metal can be oxidized, nitrided, carburized, or boronized to form a coated metal base section.

[0014] Suitable ceramics and minerals for the base section material include, but are not limited to, oxides, nitrides, carbides or borides, or any combination thereof. Suitable examples include bioactive glasses, calcium phosphates such as beta-tricalcium phosphate (TCP), biphasic calcium phosphate, and apatites such as hydroxyapatite, fluoroapatite, chlorapatite, and / or calcium-deficient apatite, and combinations thereof.

[0015] Suitable (hydrogel) polymers as base section materials include collagen, poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyacrylamide, polyurethane, polyethylene glycol (PEG), chitin, poly(hydroxyalkyl methacrylates), water-swellable N-vinyl lactams, starch graft copolymers, and derivatives and combinations thereof.

[0016] Other preferred materials for the base section include polyaryletherketone (PAEK) polymers. PAEK polymers include semi-crystalline thermoplastic polymers that contain alternating ketone (R-CO-R) and ether groups (ROR). The linking group R between the functional groups contains a 1,4-substituted aryl group. PAEK polymers used in the base section may include, among others, PEK (polyetherketone), PEEK (polyetheretherketone), PEKK (polyetherketoneketone), PEEKK (polyetheretherketoneketone) and PEKEKK (polyetherketoneetherketoneketone). Due to its excellent resistance to hydrolysis, the polyaryletherketone polymer of the base section is advantageously used in the implants of the invention. It does not degrade when sterilized or implanted in the body for extended periods of time. It also proves to bond particularly well to the elastomeric materials of the middle and upper sections.

[0017] The material used in the base section of the implant of the present invention may be used by itself or, in one embodiment, may include a reinforcing material selected from the group consisting of fibrous or particulate polymers and / or metals.

[0018] The base section of the implant of the present invention may also include a radiation-absorbing medical imaging contrast agent, such as a radiocontrast agent or an MRI contrast agent, or a radiopharmaceutical that itself emits radiation. The base section may also include small solid objects or bodies, such as beads, which may include, for example, a high melting point metal such as tantalum.

[0019] The base section of the plug-shaped implant serves as a bone anchor, while the combination of the middle and top sections serves as a partial replacement of damaged cartilage and as a scaffold for cartilage regeneration. In a plug-shaped implant, the top section refers to the section that is closest to the cartilage phase when implanted. The base section refers to the section that is furthest from the cartilage phase when implanted. The middle section is located between the top and base sections.

[0020] The cross section of the plug-shaped implant through a horizontal or vertical plane can have any suitable shape. The cross section can be circular, square, or polygonal, such as hexagonal, octagonal, or decagonal. In some embodiments, the plug-shaped implant can be tapered to be shaped as a truncated cone structure. Preferably, the implant has a smaller cross section at the base section than at the top section. The cross section (or diameter in the case of a cylindrical implant) can vary continuously between the base section and the top section, or it can show a discontinuity, for example, at the interface between the sections.

[0021] If the implant has a tapered profile, the angle of the taper is preferably 1°-45°. In some embodiments, the taper is about 3°-30°, more preferably 5°-30°, and even more preferably 10°-15°. The tapered profile may facilitate the insertion of the implant into the osteochondral defect and further reduce the possibility of damage to the host tissue. The implant is preferably used without attachment means and remains in the osteochondral structure by its geometry and the surrounding tissue structure. The implant can be used in the knee, but also in other joints such as the temporomandibular joint, ankle, hip, shoulder, etc.

[0022] According to the invention, the plug-shaped implant on top of the base section further comprises a middle section adapted to replace the cartilage tissue and a top section adapted to grow the cartilage tissue on and in, the middle section and the top section comprising the same thermoplastic elastomer material. This means that at least their building blocks are chemically the same. As will be described herein below, some physical properties may differ, for example their weight average molecular weight. The thermoplastic elastomer material is porous in the top section and non-porous in the middle section and comprises linear block copolymers comprising urethane and / or urea groups. Furthermore, the thermoplastic elastomer material is substantially free of peptide compounds having cartilage regeneration properties. Surprisingly, it has been found that the implant of the invention is capable of regenerating cartilage tissue, thus avoiding the use of any functional compounds exhibiting cartilage regeneration properties. In particular, it has been found that the implant according to this embodiment does not require the use of peptides, for example those comprising the RGD sequence. These compounds are said to allow the binding of integrins, thereby stimulating cell adhesion.

[0023] The linear block copolymers of the present invention are segmented copolymers with elastic properties resulting from hydrogen bonding interactions between the molecular chains. Such copolymers contain "hard" crystallized blocks of polyurethane and / or polyurea segments, and may also contain "hard" crystallized blocks of polyester and / or polyamide between the "soft" blocks. At room temperature, the low melting "soft" blocks may not be compatible with the high melting "hard" blocks, causing phase separation by crystallization or liquid-liquid separation. These copolymers exhibit reversible physical crosslinks resulting from the crystallization of the "hard" blocks of the segmented copolymers. Thermoplastic elastomers can be formed into any shape at higher temperatures, more specifically above the melting point of the "hard" blocks. Thermoplastic elastomers, on the other hand, provide mechanical stability and elastic properties at low temperatures, i.e., typical body temperatures. This makes these materials particularly suitable as replacement materials for human or animal cartilage.

[0024] The thermoplastic elastomer building blocks generally include three building blocks, for example a long-chain diol with a polyether, polyester or polycarbonate backbone, a difunctional diisocyanate, and finally a chain extender such as water, another (sometimes short-chain) diol, or a diamine. The latter chain extenders are preferred because they provide bis-urea units to the thermoplastic elastomer.

[0025] Preferred are embodiments of the implant in which the thermoplastic elastomer material is aliphatic. This means that all building blocks of the thermoplastic elastomer are devoid of aromatic groups and contain only aliphatic groups. The thermoplastic elastomers of the present invention can be prepared in a one-pot procedure in which a long-chain diol is first reacted with an excess of a diisocyanate to form an isocyanate-functionalized prepolymer. The latter is subsequently reacted with a chain extender, such as a preferred diamine, which results in the formation of a high molecular weight thermoplastic elastomer polymer containing urethane groups. When a diamine is used as a chain extender, the thermoplastic elastomer also contains bis-rare groups, which is preferred.

[0026] The synthetic procedures for preparing thermoplastic elastomers can lead to a distribution of "hard" block lengths. As a result, the phase separation of these block copolymers can be incomplete, with some of the "hard" blocks, especially the short ones, dissolving in the soft phase, causing an increase in the glass transition temperature. This is less desirable for the low-temperature flexibility and elasticity of the thermoplastic elastomer materials in the upper and middle sections. The polydispersity of the "hard" blocks is manifested as a wide melting range and a temperature-dependent rubbery plateau in dynamic mechanical thermal analysis (DMTA). Thus, preferred embodiments include elastomeric block copolymers that contain "hard" blocks of substantially uniform length. These can be prepared by fractionation of a mixture of "hard" block oligomers and subsequent copolymerization of uniform "hard" block oligomers of a specific length (or change in length) with the prepolymers described above.

[0027] Thermoplastic elastomers can be prepared by chain extension reaction of isocyanate-functionalized prepolymers with diamines, but also by chain extension reaction of amine-functionalized prepolymers with diisocyanates. Examples of suitable commercially available diamines and diisocyanates include alkylenediamines and / or diisocyanates, arylenediamines and / or diisocyanates. Amine-functionalized prepolymers are also commercially available or can be prepared from (readily available) hydroxy-functionalized prepolymers by cyanoethylation followed by reduction of the cyano group, Gabriel synthesis (halogenation or tosylation followed by modification with phthalimide and finally deprotection of the phthalimide group to form a primary amine), or other methods known in the art. Isocyanate-functionalized prepolymers can be prepared by reaction of hydroxy-functionalized prepolymers with diisocyanates such as, for example, isophorone diisocyanate (IPDI), 1,4-diisocyanatobutane, 1,6-diisocyanatohexane or 4,4'-methylenebis(phenylisocyanate). Alternatively, isocyanate-functionalized prepolymers can be prepared from amine-functionalized prepolymers, for example, by reaction with di-tert-butyl tricarbonate. Hydroxy-functionalized prepolymers of any kind of composition, typically with molecular weights ranging from about 500 g / mol to about 5000 g / mol, are also advantageously used. Examples include prepolymers of polyethers such as polyethylene glycol, polypropylene glycol, poly(ethylene-co-propylene) glycol and poly(tetrahydrofuran), polyesters such as poly(caprolactone) or polyadipate, polycarbonates, polyolefins, cured polyolefins such as poly(ethylene-butylene). Polycarbonates are preferred.

[0028] Particularly preferred are polycarbonate prepolymers. Such prepolymers produce implants according to an embodiment in which the thermoplastic elastomer material further comprises carbonate groups in addition to urethane and / or urea groups. Such implants have been found to better meet the objectives of the invention than other implants. They have been found to be particularly beneficial in that their mechanical properties are well matched to those of human or animal cartilage. Surprisingly, the use of this embodiment in implanted implants improves cartilage regeneration.

[0029] A particularly preferred embodiment of the present invention provides an implant wherein the thermoplastic elastomeric material comprises polyurethane-bisurea-alkylene carbonate, more preferably polyurethane-bisurea-hexylene carbonate.

[0030] Apart from the abandonment of peptide compounds with cartilage regenerating properties in the linear block copolymer, the implant facilitates the migration, integration, regeneration, proliferation, and growth of cells in and around the implant or patch composition, and / or the injury or defect, and / or promotes the healing of the injury or defect, and / or is chondrogenic and osteogenic, i.e., builds, grows, and produces cartilage and bone, respectively. These agents include, but are not limited to, cytokine compounds, chemokine compounds, chemoattractant compounds, antibacterial compounds, antiviral compounds, anti-inflammatory compounds, proinflammatory compounds, bone or cartilage regenerating molecules, cells, blood components (e.g., whole blood and platelets), and combinations thereof. Agents that increase strength and facilitate attachment may also be included in the implant. In a preferred embodiment, the elastomeric linear block copolymer does not include any compounds with cartilage regenerating properties.

[0031] Substantially non-porous material in the context of the present invention means a material with less than 20% porosity, preferably at most 10%, more preferably at most 5%, and even more preferably at most 1% of the total volume of the material. Porous material includes pores, defined as fine openings. Pores can be micropores with a diameter of less than 1 mm, and macropores with a diameter of more than 1 mm. Pores can be interconnected, which is preferred, meaning that the pores are internally connected or there is continuity between parts or elements. Non-porous material in the context of the present invention does not mean a material that is impermeable to molecules of any size, although some small molecules may actually be able to pass through the non-porous material. Rather, non-porous material in the context of the present invention refers to a material that is impermeable to synovial fluid and / or blood.

[0032] The pore size of the porous portion of the implant may be selected from 100 to 1000 microns, more preferably from 100 to 500 microns, and most preferably from 300 to 500 microns.

[0033] Thermoplastic elastomers used in the upper and middle sections of the implant are particularly advantageous since they allow their mechanical properties to be adapted to those of human and animal cartilage. In one embodiment of the invention, the elastomer material of the middle section can provide the implant with an elastic modulus at room temperature of less than 10 MPa, more preferably less than 8 MPa, less than 7 MPa, less than 6 MPa, less than 5 MPa, less than 4 MPa, less than 3 MPa, or less than 2 MPa.

[0034] In the context of the present application, room temperature means a temperature in the range of 20-30°C, more preferably a temperature of 25°C.

[0035] Similarly, preferred embodiments of the implant include a top section in which the porous elastomeric material of the top section has an elastic modulus at room temperature that is less than 80%, more preferably less than 50%, even more preferably 10-50%, even more preferably 15-40%, and most preferably 20-30% of the elastic modulus of the elastomeric material of the middle section. Such a reduction in elastic modulus can be achieved by modifying the porosity of the material of the middle section or by modifying the physical properties of the material of the middle section, for example through changing its weight average molecular weight.

[0036] The porosity of the elastomeric material of the upper section can be selected within wide limits: preferred porosity of the elastomeric material of the upper section is selected from 20 to 80% by volume, more preferably from 30 to 70% by volume, even more preferably from 40 to 60% by volume and most preferably from 45 to 55% by volume.

[0037] Useful embodiments of the present invention provide implants in which the base section comprises a core of non-porous base section material and a preferably circumferential shell of porous base section material, the shell having a thickness that is less than 10% of the maximum diameter of the base section. Other useful embodiments provide implants in which the (circumferential) shell has a thickness that is less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the maximum diameter of the base section. Alternatively, the cross-sectional area of ​​the (circumferential) shell covers up to 35% of the maximum cross-sectional area of ​​the base section. Other useful embodiments provide implants in which the cross-sectional area of ​​the (circumferential) shell is less than 30%, 25%, 20%, 15%, 10%, or 5%, 3%, or 1% of the maximum cross-sectional area of ​​the base section.

[0038] Embodiments having the above disclosed preferred combination of mechanical properties of the upper and mid-sections tend to promote cartilage regeneration, which is believed to be due to favorable stress (re)distribution in the osteochondral structure containing the implant during (dynamic) loading.

[0039] Another embodiment of the present invention provides an implant in which the base section extends between the top and bottom surfaces and includes a layer of porous base section material adjacent the top surface and has a thickness that is 10% of the maximum height of the base section, and the pores of the base section material in the layer are made of a biocompatible elastomeric material, preferably all pores. In other embodiments, the layer adjacent the top surface has a thickness that is less than 10%, less than 8%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the maximum height of the base section. All of the above embodiments can improve the adhesion of the middle section (and upper section) to the base section to various degrees. At the same time, the mechanical properties of the base section and the support provided by the base section to the implant remain at an appropriate level.

[0040] Another embodiment of the present invention relates to an implant comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer.

[0041] Yet another embodiment provides an implant wherein the base section comprises a non-porous polyaryletherketone polymer.

[0042] In another embodiment of the invention, the top surface of the base section of the implant includes irregularities or undulations. The irregularities may include, for example, ridges having a sawtooth shape. The undulations may be irregular or regular, such as sinusoidal in shape.

[0043] Another useful embodiment relates to an implant in which the base section includes a centrally located cavity containing a biocompatible elastomeric material. Such a cavity may further improve adhesion of the middle section (and the top section) to the base section. The cavity may be cylindrical and its cross section may be square or polygonal. The walls of the cavity may also be provided with irregularities or undulations or may include sections of cross-sectional area larger than its average cross-sectional area. Several of such cavity sections may be provided at different heights of the base section to form a mechanical locking structure.

[0044] Yet another embodiment provides an implant in which the base section includes an outer surface having irregularities or undulations. Such outer surface irregularities may include, for example, ridges having a sawtooth shape, extending circumferentially on (part of) the outer surface of the base section. The undulations may be irregular or regular, such as of a sinusoidal shape. The undulations may also extend circumferentially on (part of) the outer surface of the base section. The irregularities and undulations may be provided by casting the material in a suitably profiled mold, or alternatively by machining, for example by a rotary milling machine of a molded implant.

[0045] Useful embodiments of the invention provide implants in which the midsection comprises a core of non-porous elastomeric material and a circumferential shell of porous elastomeric material, the shell having a thickness of less than 10% of the maximum diameter of the midsection. Other useful embodiments provide implants in which the circumferential shell has a thickness of less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the maximum diameter of the midsection. The maximum diameter is appropriate, for example, in embodiments in which the plug-shaped implant is tapered and has a circular cross-section. Alternatively, the cross-sectional area of ​​the circumferential shell covers up to 35% of the maximum cross-sectional area of ​​the midsection. Other useful embodiments provide implants in which the cross-sectional area of ​​the circumferential shell is less than 30%, 25%, 20%, 15%, 10%, 5%, 3%, or 1% of the maximum cross-sectional area of ​​the midsection. The maximum cross-sectional area is appropriate, for example, in embodiments in which the plug-shaped implant is tapered.

[0046] The height of the plug-type implant may be selected depending on the particular application in the body. The height may vary, for example, from 3 to 18 mm. According to a useful embodiment of the present invention, an implant is provided in which the height of the base section, the height of the non-porous middle section, and the height of the porous top section are selected such that, when implanted, the top surface of the implant is located below the top surface of the cartilage present on the osteochondral structure, preferably over a distance of 0.1 to 1 mm. This embodiment encourages the growth of cartilage tissue not only in but also on the top section, thereby building a strong fixation between the top section and the newly formed cartilage. It has been found that chondrocytes from the host cartilage have a strong affinity for the segmented elastomer of the top section and therefore tend to colonize its surface to generate new hyaline cartilage tissue on the top of the implant.

[0047] Another embodiment provides an implant in which the height of the base section, the height of the non-porous middle section, and the height of the porous top section are selected such that the bottom surface of the middle section is approximately the same height as the bottom surface of the cartilage present on the osteochondral structure at the time of implantation.

[0048] Yet another embodiment of the present invention provides a top section whose top surface is slightly curved. The preferred radius of curvature of the top surface of the top section in the sagittal plane is selected in the range of 15-150 mm, more preferably 17-125 mm, even more preferably 19-100 mm, even more preferably 21-75 mm, even more preferably 23-50 mm, and most preferably 25-30 mm. This embodiment can regenerate a new cartilage layer on the top surface of the top section of the implant with a thickness that is approximately equal across the top surface. The result can be a radius of the top surface of the regenerated cartilage that is approximately the same as the radius of the surrounding natural cartilage layer next to the implant, thereby showing a continuity of radii. The top surface of the top section of the implant can also be curved in the medial-lateral plane, preferably with a radius of curvature having the range disclosed above for the sagittal plane. In a practical embodiment, the top surface of the top section of the implant has equal radii of curvature in the sagittal and medial-lateral planes. This embodiment therefore includes a spherical top surface.

[0049] Another aspect of the present invention provides a method for the preparation of an implant. A method for the preparation of an implant is provided, the method comprising: a) providing in a mold at room temperature a base section comprising a base section material comprising one of a biocompatible metal, a ceramic, a mineral such as a phosphate mineral, and a polymer, optionally a hydrogel polymer, and a combination thereof, and a base section comprising granules of a thermoplastic elastomer material on top of the base section, the thermoplastic material comprising a linear block copolymer comprising urethane and urea groups, substantially free of added additional peptide compounds having cartilage regeneration properties; b) closing the mold and heating the above assembly to a temperature of 100° C.-250° C. under a pressure of 1-2 GPa so that the thermoplastic elastomer material melts and fuses with the base section; c) cooling the assembly to room temperature to solidify the thermoplastic elastomer material and opening the mold; d) providing pores in the upper section of the thermoplastic elastomeric material either before or after the mold is opened.

[0050] A preferred embodiment of the method comprises step a), in which a base section comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer, and granules of a thermoplastic elastomer material on top of the base section are provided in a mould at room temperature.

[0051] Another embodiment of the invention provides a method in which after step b) the mould is opened, additional granules of thermoplastic elastomer material are added to the mould and step b) is repeated. The amount of material added in the two-step embodiment of this method can be selected within wide limits. Increasingly better results are obtained when the ratio between the first and second addition of granules of thermoplastic elastomer material is selected from 01:99 to 99:01, more preferably from 30:70 to 97:03 and most preferably from 70:30 to 95:05.

[0052] Another embodiment of the present invention provides a process, wherein the heating temperature in step b) is from 110° C. to 225° C., more preferably from 120° C. to 200° C., most preferably from 130° C. to 175° C. The preferred pressure in all the cited temperature ranges is from 1.1 to 1.8 GPa, more preferably from 1.2 to 1.6 GPa.

[0053] Yet another aspect of the present invention relates to a method for the preparation of a thermoplastic elastomer material comprising a linear block copolymer comprising urethane and urea groups and substantially free of additional peptide compounds having cartilage regenerative properties, the method comprising the steps of: - preparing an isocyanate-terminated prepolymer by reacting a diol with a diisocyanate; - polymerizing an isocyanate-terminated prepolymer by chain extension with a diamine, The above steps are carried out to the exclusion of peptide compounds having cartilage regenerative properties, more preferably to the exclusion of any compound having cartilage regenerative properties.

[0054] In a preferred method according to one embodiment, the diol is selected from polyester diols, polyether diols, preferably carbonate diols, and combinations thereof.

[0055] Another preferred embodiment provides a process wherein the diisocyanate comprises an n-alkylene-diisocyanate.

[0056] Yet another preferred embodiment of the present invention relates to a process in which the diamine comprises a primary diamine, preferably an n-alkylene-diamine. [Brief description of the drawings]

[0057] The present invention will now be further elucidated by the following figures and examples, but is not limited thereto.

[0058] [Figure 1A-1D] 1A-1D show schematic side views of four embodiments of exemplary implants according to the present invention. [Figure 2A] FIG. 2 shows a schematic perspective view of a base section according to one embodiment of the present invention. [Figure 2B] FIG. 2B shows a schematic cross-sectional view of the embodiment of FIG. 2A. [Fig. 2C-2D] FIG. 2C shows a schematic detail view of parts B and C of the embodiment of FIG. 2B. [Diagram 3] FIG. 1 shows a schematic diagram of a possible synthetic route to a thermoplastic polycarbonate material, according to one embodiment of the present invention. [Figure 4]1 shows a 1H-NMR spectrum of a thermoplastic polycarbonate material according to an embodiment of the present invention. [Figure 5A-5C] 1 shows DSC thermograms of a thermoplastic polycarbonate material according to an embodiment of the present invention at different heating rates. [Figures 6A-6C] 6A shows a schematic diagram of a defect in an osteochondral structure (6A), an osteochondral structure comprising an implant according to an embodiment of the invention (6B), and the same osteochondral structure after cartilage overgrowth / ingrowth (6C). [Figure 7A-7D] 13A-13D show schematic side views of four embodiments of implants according to further embodiments of the present invention. [Figure 8A-8C] 8A-8C show schematic diagrams of a defect in an osteochondral structure (8A), an osteochondral structure comprising an implant according to another embodiment of the invention (8B), and the same osteochondral structure after cartilage overgrowth / ingrowth (8C).

[0059] Referring to FIG. 1A, a side view of an exemplary embodiment of an implant according to the present invention is shown. The implant 1, in the shape of a plug, includes a base section 2 configured to be fixed to bone tissue, a middle section 3 configured to replace cartilage tissue, and a top section 4 configured to allow cartilage tissue to grow on and into it. The middle section 3 and the top section 4 include the same thermoplastic elastomer material. The thermoplastic elastomer material in this embodiment includes polyurethane-bisurea-hexylene carbonate, the preparation and properties of which are elucidated further below. However, the top section 4 includes a porous polyurethane-bisurea-hexyl carbonate, while the middle section 3 includes the same polyurethane-bisurea-hexyl carbonate without pores. The base section 2 includes a non-porous polyaryletherketone polymer, which in the embodiment shown is a non-porous PEKK polymer. The implant 1 is cylindrical and has a diameter 10 of 6 mm. The height 20 of the base section 2, the height 30 of the middle section 3, and the height 40 of the top section 4 add up to a height of up to 6 mm.

[0060] FIG. 1B represents a schematic side view of another embodiment of an implant according to the invention. The embodied implant 1, in the form of a plug, again comprises a base section 2 configured for anchoring to bone tissue, a middle section 3 configured for replacing cartilage tissue, and a top section 4 configured for growing cartilage tissue on and into it. The middle section 3 and the top section 4 comprise the same polyurethane-bisurea-hexylene carbonate material, which is porous in the top section 4 and non-porous in the middle section 3. The base section 2 comprises a substantially non-porous PEKK polymer having a porosity of less than 20% relative to the total volume of the PEKK polymer. The base section 2 of this embodiment comprises, inter alia, a core 21 of non-porous PEKK polymer and a circumferential shell 22 of porous PEKK polymer. The shell 22 has a thickness 23 of about 8% of the diameter 10 of the base section 2 (and of the implant 1). The base section 2 further extends between the top surface 24 and the bottom surface 25 and includes a layer 26 of porous PEKK polymer adjacent the top surface 24 and having a thickness 27 of about 8% of the height 20 of the base section 2. The pores of the PEKK polymer of the layer 26 originate from the middle section 3 and include a biocompatible polyurethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer of the layer 26 during manufacture. The method for the manufacture of the implant is further described below. As with the embodiment of FIG. 1A, the implant 1 is cylindrical and has a diameter 10 of 6 mm. The height 20 of the base section 2, the height 30 of the middle section 3, and the height 40 of the top section 4 add up to a height of 6 mm.

[0061] 1C represents a schematic side view of yet another embodiment of an implant according to the invention. The embodied implant 1, in the form of a plug, again comprises a base section 2 adapted for anchoring to bone tissue, a middle section 3 adapted for replacing cartilage tissue, and a top section 4 adapted for growing cartilage tissue on and into it. The middle section 3 and the top section 4 comprise the same polyurethane-bisurea-hexylene carbonate material, which is porous in the top section 4 and substantially non-porous in the middle section 3. The base section 2 comprises a substantially non-porous PEKK polymer having a porosity of less than 20% relative to the total volume of the PEKK polymer. The base section 2 of this embodiment in particular extends between a top surface 24 and a bottom surface 25 and comprises a layer 26 of porous PEKK polymer, which layer 26, adjacent to the top surface 24, has a thickness 27 of about 8% of the height 20 of the base section 2. The pores of the PEKK polymer of layer 26 originate from mid-section 3 and include biocompatible polyurethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer of layer 26 during manufacture. Mid-section 3 of this embodiment includes, among other things, a core 31 of non-porous polyurethane-bisurea-hexylene carbonate polymer and a circumferential shell 32 of porous poly-urethane-bisurea-hexylene carbonate polymer. Shell 32 has a thickness 33 of about 8% of the diameter 10 of mid-section 3 (and implant 1). Base section 2 further extends between top surface 24 and bottom surface 25 and includes a layer 26 of porous PEKK polymer adjacent top surface 24 and having a thickness 27 of about 8% of the height 20 of base section 2. The dimensions and shape are the same as the embodiment of Figures 1A and 1B.

[0062] FIG. 1D shows a schematic side view of yet another embodiment of an implant according to the invention. The embodied implant 1, in the form of a plug, corresponds to that shown in FIG. 1C. Furthermore, the middle section 3 of this embodiment has a circumferential shell 32 of porous poly-urethane-bisurea-hexylene carbonate polymer with a thickness 33 of about 10% of the diameter 10 of the middle section 3 (and of the implant 1). Furthermore, the base section 2 comprises a layer 26 of porous PEKK polymer, adjacent to the upper surface 24 and having a thickness 27 of about 5% of the height 20 of the base section 2. The pores of the PEKK polymer of the layer 26 originate from the middle section 3 and comprise biocompatible poly-urethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer of the layer 26 during manufacture. The base section 2 further comprises a core 21 of non-porous PEKK polymer and a circumferential shell 22 of porous PEKK polymer. The shell 22 has a thickness 23 that is about 5% of the diameter 10 of the base section 2 (and implant 1). Finally, the base section 2 also includes a layer 28 of porous PEKK polymer adjacent the bottom surface 25 and having a thickness 29 that is about 5% of the height 20 of the base section 2. The dimensions and shape are the same as the embodiment of Figures 1A-1C.

[0063] 1B, 1C, and 1D, the circumferential shells (22, 32) are shown in cross section to show their respective thicknesses (23, 33). In side view, they extend across the entire diameter 10 of the implant 1.

[0064] With reference to Figure 7A, a side view of another embodiment of an implant according to the invention is shown. The implant 1, which is in the form of a plug, comprises the same materials and sections as shown in Figure 1A. The dimensions of the implant in Figure 7A are the same as those of the implant in Figure 1A, with one exception. Instead of having a flat upper surface 41 of the upper section 4 (and thus the implant 1), as in Figure 1A, the upper surface 41a of the upper section 4 is spherical (not drawn to scale) with a radius of curvature R of about 28 mm.

[0065] With reference to Figure 7B, a side view of another embodiment of an implant according to the invention is shown. The implant 1, which is in the form of a plug, comprises the same materials and sections as shown in Figure 1B. The dimensions of the implant in Figure 7B are the same as those of the implant in Figure 1B, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in Figure 1B, the upper surface 41a of the upper section 4 is spherical (not drawn to scale) with a radius of curvature R of about 28 mm.

[0066] Referring to Figure 7C, a side view of another embodiment of an implant according to the invention is shown. The implant 1, which is in the form of a plug, comprises the same materials and sections as shown in Figure 1C. The dimensions of the implant in Figure 7C are the same as those of the implant in Figure 1C, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in Figure 1C, the upper surface 41a of the upper section 4 is spherical (not drawn to scale) with a radius of curvature R of about 28 mm.

[0067] With reference to Figure 7D, a side view of another embodiment of an implant according to the invention is shown. The implant 1, which is in the form of a plug, comprises the same materials and sections as shown in Figure 1D. The dimensions of the implant in Figure 7D are the same as those of the implant in Figure 1D, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in Figure 1D, the upper surface 41a of the upper section 4 is spherical (not drawn to scale) with a radius of curvature R of about 28 mm.

[0068] Again, note that in Figures 7B, 7C, and 7D, the circumferential shells (22, 32) are shown in cross section to show their respective thicknesses (23, 33). In side view, they span the full diameter 10 of the implant 1 (not drawn to scale).

[0069] 2A-2D, an embodiment of the base section 2 of the implant 1 of the present invention is shown in schematic form. The base section 2 shown is essentially cylindrical with a diameter of 10 and a height of 20. The upper surface 24 of the base section has a circumferentially flat rim portion 240 that gradually extends into a centrally located cavity 241. The cavity 241 is provided with a locking portion 242 having a diameter larger than that of the cavity 241. As shown in detail in FIG. 2C, the locking portion 242 of the cavity 241 is disc-shaped, whereby the outer edge of the disc forms an angle 246 of 1°-20°, more preferably 5°-15°, with the longitudinal direction 247 of the base section 2. The cavity 241 (and portion 242) during manufacture of the implant is filled with a portion of a biocompatible elastomeric material to provide a suitable fixation of the intermediate section 3 to the base section 2. As discussed above, the base section 2 comprises a PEKK polymer that may be non-porous or substantially non-porous, the latter embodiment including the examples disclosed above. The base section 2 can further be seen to include an outer surface having irregularities or undulations. In this embodiment these include circumferential ridges 243 that are sawtooth in cross section, as shown in detail in Figure 2D. The angle 244 at which the sawtooth flanks extend relative to the lateral direction 245 of the base section 2 is preferably between 70° and 85°, more preferably between 75° and 80°.

[0070] Preparation of elastomeric materials for the upper and middle sections Example 1: Polycarbonate-Aliphatic: Poly(hexylene carbonate urethane)-bisurea biomaterial MVH313, see Table 1 below. This one-pot, two-step fabricated biomaterial, MVH313, was prepared by functionalization of 1.0 molar equivalent of poly(hexylene carbonate) diol (MW = 2000) with 2.0 molar equivalents of 1,6-diisocyanatohexane (step 1), followed by chain extension using 1.0 molar equivalent of 1,6-diaminohexane (step 2).

[0071] In particular, the aliphatic poly-urethane-urea-hexylene carbonate biomaterials of middle section 3 and top section 4 were prepared as follows (see FIG. 3). Poly(hexylene carbonate) diol (MW=2000, 23.9 g, 11.9 mmol) was weighed into a 500 mL three-neck flask and dried by heating at 75° C. overnight under vacuum and then allowed to cool to room temperature. Under an argon atmosphere, 1,6-diisocyanatohexane (4.1 g, 23.9 mmol), DMAc (20 mL) and one drop of Sn(II) bis(2-ethylhexanoate) were added, and the mixture was then heated and stirred for 3 hours to increase the viscosity. The mixture was cooled to room temperature, diluted with DMAc (100 mL), and a solution of 1,6-diaminohexane (1.4 g, 11.9 mmol) in DMAc (50 mL) was added in one portion with thorough mixing. A gel formed immediately upon addition and mixing. The mixture was further diluted with DMAc (150 mL) and heated in an oil bath at 130 °C to obtain a homogeneous viscous slurry. After cooling to room temperature, the mixture was precipitated in a water / brine mixture (2.75 L water + 0.25 L saturated brine) to obtain a soft white material. This material was cut into smaller pieces and stirred in a 1:5 mixture of methanol and water (3 L) for 64 h. After decanting the supernatant, the resulting solid was stirred in a 2:1 mixture of methanol and water (0.75 L) for 6 h. The supernatant was decanted and stirred in a 2:1 mixture of methanol and water (0.75 L) for 16 h, the supernatant was decanted, and the solid was dried in vacuum at 70 °C to obtain a flexible, tough elastomeric polymer.

[0072] 1 H NMR spectroscopy was performed on the resulting polymers using a Varian 200, Varian 400 MHz, or 400 MHz Bruker spectrometer at 298 K. DSC was performed using a Q2000 machine (TA Instruments). For evaluation of melting temperature (Tm) and glass transition temperature (Tg), heating scan rates of 10 °C / min and 40 °C / min were used, respectively. Tm was determined by the peak melting temperature, and Tg was determined from the inflection point.

[0073] All reagents, chemicals, materials, and solvents were obtained from commercial sources and used without further purification. The average molecular weight of the poly(hexylene carbonate) diol used was about 2 kg / mol. Figures 4 and 5 show the results of the polymerization of the resulting polymer, respectively. 1 The H NMR spectrum and DSC thermogram are shown as follows: 1 The results of the H NMR spectra can be summarized. 1 H NMR (400MHz, HFIP-D2): δ=4.23(M,N * 4H, N~14.3), 4.10 (M, 4H), 3.17 (M, 12H), 1.87-1.32 (multiple signals of aliphatic CH2 methylene) ppm. The average molecular weight of the repeating hard / soft block sections is about 2.5 kDa. The DSC results can be summarized as follows: DSC (10 °C / min, Fig. 5A): Tm (top) = 20.9 °C (soft block melting), DSC (40 °C / min, Fig. 5B): Tg = -38.0 °C. The second melting point of the hard block was not observed until 200 °C. However, in the final heating run to 250 °C at 10 °C / min (Fig. 5C), a small and broad melting transition was observed at about 227 °C. In the DSC diagram, the endothermic melting peak is plotted downwards and the exothermic crystallization is plotted upwards.

[0074] The non-porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial had an elastic modulus of 3.6±0.03 MPa according to ASTM D638.

[0075] Example 2: Polyether-aromatic:poly(tetrahydrofuranurethane)-bisurea biomaterial MVH309B, see Table 1 below. Biomaterial MVH309B was also prepared in a one-pot, two-step experimental procedure similar to that detailed for biomaterial MVH313. In particular, biomaterial MVH309B was prepared by functionalization of 1.0 molar equivalent of polytetrahydrofuran diol (MW=2000) with 1.33 molar equivalent of bis(4-isocyanatophenyl)methane (MDI) (step 1), followed by chain extension using 0.33 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH309B was isolated as a white, flexible, and tough elastomeric polymer.

[0076] Example 3: Polyether-Aliphatic: Poly(tetrahydrofuran urethane)-bisurea biomaterial MVH312, see Table 1 below. Biomaterial MVH312 was also produced in a one-pot, two-step experimental procedure similar to that detailed for biomaterial MVH313. In particular, biomaterial MVH312 was prepared by functionalizing 1.0 molar equivalent of polytetrahydrofuran diol (MW=2000) with 2.0 molar equivalent of 1,6-diisocyanatohexane (step 1), followed by chain extension using 1.0 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH312 was isolated as a flexible, tough, elastomeric polymer.

[0077] Example 4: Polycarbonate-aromatic:poly(hexylene carbonate urethane)-bisurea biomaterial MVH311, see Table 1 below. Biomaterial MVH311 was also prepared in a one-pot, two-step experimental procedure similar to that detailed for biomaterial MVH313. In particular, biomaterial MVH311 was prepared by functionalizing 1.0 molar equivalent of poly(hexylene carbonate) diol (MW=2000) with 1.33 molar equivalent of bis(4-isocyanatophenyl)methane (MDI) (step 1), followed by chain extension using 0.33 molar equivalent of 1,6-diaminohexane (step 2). Biomaterial MVH311 was isolated as a flexible, tough, elastomeric polymer.

[0078] Mechanical properties of the mid-section elastomeric material Stress relaxation tests were performed on two aromatic and two aliphatic polymers from Examples 1-4, and on three equine cartilage specimens obtained from the Utrecht Medical Center. A description of the specimens (e.g., polymer class) and their dimensions are shown in Table 1. Using an Instron Electropulse E10000, each specimen was compressed to a strain of 0.05 mm / mm at a strain rate of 0.005 s-1 and held constant for 1800 seconds. All tests were performed in triplicate. During the tests, the load, displacement, and time were recorded, and stress relaxation curves were subsequently obtained from the data. Stress relaxation is demonstrated by determining the stress relaxation coefficient G(t) at the start of stress relaxation (G(0)) and 1800 seconds after the start of stress relaxation (G(1800)) using the following equation: G(t)=σ(t) / ε0, where σ(t) is the compressive stress and ε0 is the set (constant) strain. [Table 1]

[0079] The results are shown in Table 2 below. [Table 2]

[0080] Preparation of biomaterial-covered PEKK bone anchors The implant 1 was fabricated by attaching the top and middle sections (4, 3) to a PEKK base section 2, which serves as a bone anchor. In a method according to an embodiment of the invention, the PEKK bone anchor was capped with a poly-urethane-urea-hexylene carbonate biomaterial by forcing small granules of an aliphatic polycarbonate polymer onto and into the PEKK anchor. A custom press set configuration was used for this purpose. Various temperatures (100°C to about 150°C), compression forces (2kN to about 4kN), and methods have been tested. The best results were obtained using a two-stage procedure using a temperature of 150°C and a compression force of 40kN (equivalent to 4 tons or 4000 kg, a pressure of 1.4 GPa). Temperatures lower than 150°C seemed to result in a non-uniformly pressed poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4), while higher temperatures are less desirable since the urea groups in the poly-urethane-urea-hexylene carbonate biomaterial may subsequently decompose to some extent. In the first step, approximately 50 mg of polymer 12 was pressed onto or into the PEKK bone anchor for 15 min, whereas in the second step, approximately 2 mg of polymer 12 was added to the setup and the sample was pressed for another 15 min at the same conditions (150 °C, 40 kN). The sample was subsequently removed from the compression setup and then allowed to cool. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4) on top of base section 2 appeared substantially flat. The biomaterial was nearly transparent and colorless. The edges of the biomaterial showed some fringing or fraying, which were removed using a scalpel.

[0081] The central hole (241, 242) in the base section 2 was approximately 4.5 mm deep and 2 mm in diameter. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and the attachment of the biomaterial to the PEKK base section 2 appeared to be very strong and robust. It proved virtually impossible to remove the biomaterial from the PEKK base section by force or to loosen the connection at the PEKK-biomaterial interface. All used instruments and accessories intended to be in contact with the PEKK base section 2 and / or the elastomeric biomaterial were rinsed with ethanol or isopropanol and then dried. After pressing and cutting any fraying, the PEKK-biomaterial plug implant was rinsed with isopropanol and dried. Plugs can also be manufactured in a sterile environment, if necessary.

[0082] As assessed by measurements, the PEKK base section was 6 mm in diameter and 6 mm in height (6 mm in height). The central cavity in the base section was approximately 2 mm in diameter and 4.5 mm in depth. The elastomeric biomaterial (aliphatic polycarbonate) placed in the PEKK base section was approximately 6 mm in diameter and 1 mm in height. Thus, the total height of the PEKK-biomaterial plug implant was approximately 7 mm.

[0083] The upper section 4 was made porous by drilling holes therein with an average diameter of 300 microns, resulting in a final porosity of 50% by volume. The porous aliphatic polyurethane-urea-hexylene carbonate biomaterial of the upper section 4 had an elastic modulus of 0.9±0.2 MPa according to ASTM D638.

[0084] The implant 1 may be implanted into an osteochondral defect 8, as shown in Figures 6A-6C. In a typical method, a cartilage defect extending into the subchondral bone (Figure 6A) is drilled out, and a plug-shaped implant 1 is embedded ("pressed in") into the drilled hole under constant pressure, as shown in Figure 6B. Bone then grows onto the PEKK base section 2, and in some embodiments, fixes the implant 1. As shown in Figure 6C, the surrounding natural cartilage 5 grows onto the upper surface 41 of the top section 4, and new cartilage 5a is generated on the top of the implant 1. As also shown in Figure 6C, the height 20 of the base section 2, the height 30 of the non-porous middle section 3, and the height 40 of the porous top section 4 are selected such that the upper surface 41 of the implant 1, when implanted, is located below the upper surface 50 of the cartilage 5 present on the osteochondral structure (5, 6), preferably over a distance 51 of 0.1-1 mm. In this case, this distance was about 0.5 mm. The osteochondral structure (5, 6) comprises the subchondral bone 6 and a cartilage layer 5 above it. A synovial cavity 7 is also typically present.

[0085] As also shown in Figures 6B and 6C, the height 20 of the base section 2, the height 30 of the non-porous middle section 3, and the height 40 of the porous upper section 4 are such that the bottom surface 24 of the middle section 3 (or the upper surface 24 of the base section 2) is approximately the same height as the bottom surface 51 of the cartilage layer 5 of the osteochondral structure (5, 6) when implanted.

[0086] Preparation of biomaterial-capped metallic bone anchors Another embodiment of the implant 1 was produced by attaching the top and middle sections (4, 3) to a titanium base section 2, which served as a bone anchor. The titanium used was the alloy Ti6A14V, which is readily commercially available. The titanium base section was provided with pores with an average pore size of about 300 microns. In a method according to an embodiment of the invention, the titanium bone anchor was capped with a poly-urethane-urea-hexylene carbonate biomaterial by forcing small granules of an aliphatic polycarbonate polymer onto and into the pores of the titanium anchor. For this purpose, the same custom press setup was used as in the previous example. Optimal results were again obtained using a two-stage procedure using a temperature of 150°C and a compression force of 40 kN (4 tons or 4000 kg, corresponding to a pressure of 1.4 GPa). In a first step, approximately 50 mg of elastomeric polymer was pressed onto and into the titanium bone anchor for 15 min, and in a second step, approximately 2 mg of elastomeric polymer was added to the setup and the sample was pressed for another 15 min under the same conditions (150 °C, 40 kN). The sample was subsequently removed from the compression setup and then allowed to cool. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4) on top of base section 2 appeared substantially flat. The biomaterial was nearly transparent and colorless. Some edges of the biomaterial showed fringes or fraying, which were removed using a scalpel.

[0087] Similar to the PEKK base anchor, the titanium base anchor was provided with a central hole (241, 242) of the same dimensions. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and attachment of the biomaterial to the titanium base section 2 was satisfactory.

[0088] The titanium base section 2 had the same dimensions as the PEKK base section. Because the same mold was used, the elastomeric biomaterial (aliphatic polycarbonate) placed in the titanium base section was approximately 6 mm in diameter and 1 mm in height. Thus, the overall height of the titanium biomaterial plug implant was approximately 7 mm.

[0089] The upper section 4 was made porous by drilling holes therein with an average diameter of 300 microns, resulting in a final porosity of 50% by volume. The porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the upper section 4 had an elastic modulus of 0.9±0.2 MPa according to ASTM D638.

[0090] The implant 1 may be implanted into the osteochondral defect 8, as already explained above, as shown in Figures 6A-6C. In a typical method, a cartilage defect extending into the subchondral bone (Figure 6A) is drilled out, and a plug-shaped implant 1 is embedded into the drilled hole, as shown in Figure 6B. Due to the relatively high stiffness of the titanium base section 2, a press-fit was not appropriate. Instead, the dimensions of the drilled-out subchondral bone were slightly larger than those of the titanium base section 2. It can be seen that the bone grows into the titanium base section 2, anchoring the implant 1. As shown in Figure 6C, the surrounding natural cartilage 5 grows onto the upper surface side 41 of the top section 4, and new cartilage 5a is generated on the top of the implant 1. As also shown in Figure 6C, the height 20 of the base section 2, the height 30 of the non-porous middle section 3, and the height 40 of the porous top section 4 are selected such that the top surface 41 of the implant 1, when implanted, is located below the top surface 50 of the cartilage 5 present on the osteochondral structure (5, 6), preferably over a distance 51 of 0.1-1 mm. In this case, this distance was about 0.5 mm. The osteochondral structure (5, 6) comprises a subchondral bone 6 and an overlying cartilage layer 5. A synovial cavity 7 is also typically present.

[0091] As also shown in Figures 6B and 6C, the height 20 of the base section 2, the height 30 of the non-porous middle section 3, and the height 40 of the porous top section 4 are selected such that the bottom surface 24 of the middle section 3 (or the top surface 24 of the base section 2) is approximately the same height as the bottom surface 51 of the cartilage layer 5 of the osteochondral structure (5, 6) when implanted.

[0092] Finally, an implant according to the embodiment shown in Figures 7A-7D may also be implanted into an osteochondral defect 8, as shown in Figures 8A-8C. Due to the spherical upper surface 41a of the upper layer 4, this embodiment may regenerate a new cartilage layer 5a on the upper surface 41a of the upper section 4 of the implant 1, of approximately equal thickness across the upper surface 41a. The result may be a radius of the upper surface 50 of the regenerated cartilage 5a that is approximately the same as the radius of the surrounding natural cartilage layer 5 adjacent to the implant, thereby showing a continuity of radii.

[0093] It will be apparent to those skilled in the art that many variations and applications of the invention are possible within the scope of the appended claims.

Claims

1. A non-biodegradable implant for replacement and regeneration of biological tissue in the form of a plug, comprising a base section adapted for fixing to bone tissue, a middle section adapted for replacing cartilage tissue of the intermediate and deep zones of a cartilage layer and having a thickness of at least 0.2 mm, and a top section adapted for growing cartilage tissue onto and into it, thus regenerating a superficial zone of said cartilage layer, said middle and top sections comprising the same non-biodegradable thermoplastic elastomer material, said non-biodegradable thermoplastic elastomer material being porous in said top section and non-porous in said middle section, said thermally degradable thermoplastic elastomer material being porous in said top section and non-porous in said middle section, A non-biodegradable implant, wherein the plastic elastomer material comprises a linear block copolymer comprising urethane and urea groups and is substantially free of additional peptide compounds having cartilage regeneration properties, said base section material comprises one of a biocompatible metal, such as titanium or a titanium alloy, a ceramic, such as sintered crystalline hydroxyapatite, a mineral, such as a phosphate mineral, and a non-biodegradable polymer, and combinations thereof, and said base section comprises a core of non-porous base section material and a circumferential shell of porous base section material, wherein the cross-sectional area of ​​the circumferential shell covers up to 35% of the maximum cross-sectional area of ​​the base section.

2. The implant of claim 1 , wherein the thermoplastic elastomeric material further comprises a carbonate group.

3. The implant of claim 1 or 2, wherein the thermoplastic elastomer material comprises a poly-urethane-bis-urea-alkylene carbonate.

4. The implant of any one of claims 1 to 3, wherein the thermoplastic elastomer material is aliphatic.

5. An implant according to any one of claims 1 to 4, wherein the elastomeric material of the intermediate section has an elastic modulus at room temperature of less than 10 MPa, more preferably less than 5 MPa.

6. The implant of any one of claims 1 to 5, wherein the porous elastomeric material of the top section has an elastic modulus at room temperature that is less than 80% of the elastic modulus of the elastomeric material of the middle section.

7. 7. The implant of any one of claims 1 to 6, wherein the base section comprises a core of the non-porous base section material and a circumferential shell of the porous base section material, the shell having a thickness that is less than 10% of the maximum diameter of the base section.

8. 8. The implant of claim 1, wherein the base section extends between a top surface and a bottom surface and comprises a layer of porous base section material, the layer adjacent the top surface and having a thickness that is less than 10% of a maximum height of the base section, and pores of the base section material within the layer comprise a biocompatible elastomeric material.

9. 9. The implant of any one of claims 1 to 8, wherein the base section material comprises a metal selected from titanium, zirconium, chromium, aluminum, stainless steel, hafnium, tantalum or molybdenum, and alloys thereof, or any combination thereof.

10. The implant of any one of claims 1 to 9, wherein the base section material comprises a ceramic or mineral selected from oxides, nitrides, carbides and borides, or any combination thereof.

11. 11. The implant of any one of claims 1 to 10, wherein the base section material comprises collagen, poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyacrylamide, polyurethane, polyethylene glycol (PEG), chitin, poly(hydroxyalkyl methacrylate), water swellable N-vinyl lactam, starch graft copolymer, and derivatives thereof, and combinations thereof.

12. 12. The implant of any one of claims 1 to 11, wherein the base section material comprises a non-hydrogel polymer, preferably a polyaryletherketone polymer such as polyether-ketone-ketone (PEKK), polyether-ether-ketone (PEEK), and polyether-ketone-ether-ketone-ketone (PEKEKK).

13. 13. The implant of claim 12, comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer.

14. 14. The implant of claim 12 or 13, wherein the base section comprises a non-porous polyaryletherketone polymer.

15. An implant according to any one of claims 1 to 14, further comprising a contrast agent or radiopharmaceutical or body for medical imaging, preferably provided in said base section.

16. The implant of any one of claims 1 to 15, wherein the upper surface of the base section comprises irregularities or undulations.

17. The implant of any one of claims 1 to 16, wherein the base section comprises a centrally located cavity containing the elastomeric material.

18. The implant of any one of claims 1 to 17, wherein the base section comprises an outer surface having irregularities or contours.

19. 19. An implant according to any one of claims 1 to 18, wherein the height of the base section, the height of the non-porous middle section and the height of the porous top section are selected such that the upper surface of the implant, when implanted, is below the upper surface of the cartilage present on the osteochondral structure, preferably by a distance of 0.1 to 1 mm.

20. 20. The implant of any one of claims 1 to 19, wherein the height of the base section, the height of the non-porous middle section and the height of the porous top section are selected such that the bottom surface of the middle section, when implanted, is approximately at the same level as the bottom surface of the cartilage present on the osteochondral structure.

21. An implant according to any one of claims 1 to 20, comprising an upper section with a slightly curved upper surface, having a radius of curvature in the sagittal plane and / or in the medial-lateral plane in the range of 15mm to 150mm.

22. The implant of any one of claims 1 to 21, wherein the base section material comprises a reinforcing material selected from the group consisting of fibrous or particulate polymers and / or metals.

23. A method for the preparation of an implant according to any one of claims 1 to 22, comprising: a) providing a base section in a mold at room temperature, said base section comprising a base section material comprising one of a biocompatible metal, a ceramic, a mineral such as a phosphate mineral, and a polymer, optionally a hydrogel polymer, and combinations thereof, and granules of a thermoplastic elastomer material on top of said base section, said thermoplastic material comprising a linear block copolymer comprising urethane and urea groups, and being substantially free of additional peptide compounds having cartilage regeneration properties; b) closing the mold and heating the above assembly to a temperature of 100° C. to 250° C. under a pressure of 1 to 2 GPa such that the thermoplastic elastomer material melts and fuses with the base section; c) cooling the assembly to room temperature to solidify the thermoplastic elastomer material and opening the mold; d) providing pores in a top section of said thermoplastic elastomeric material either before or after opening of said mold.

24. 24. The method of claim 23, wherein after step b), the mold is opened, additional granules of the thermoplastic elastomeric material are added to the mold, and step b) is repeated.

Citation Information

Patent Citations

  • Surgical prosthesis with biodegradable and non-biodegradable regions

    JP2008509752A

  • Biodegradable polyurethanes and use thereof

    US20050013793A1

  • Device for cartilage repair

    US20080262618A1

  • Biodegradable ostochondreal implant

    US20090164014A1

  • Orthopedic implants having gradient polymer alloys

    US20120209396A1